Science Oriented Solutions (SOS) and Clinical Solutions (CS), Publicis Healthcare Communications Group (PHCG) companies, today announced the successful completion of merging their operations.
Atlanta, Georgia -- April 6, 2005 -- Science Oriented Solutions (SOS) and Clinical Solutions (CS), Publicis Healthcare Communications Group (PHCG) companies, today announced the successful completion of merging their operations. President and Chief Operating Officer of SOS Evan Demestihas, M.D., RPh. will oversee the joint operation.
"Merging the two operations follows a natural synergy that will enable them to expand the range of services they provide to their clients," said Dr. Demestihas.
SOS, founded in 1997, is the first and leading contract medical affairs organization providing outsourcing for essential medical affairs activities. SOS is widely recognized as the sector leader in providing contract medical science liaison services. CS, in operation since 1994, is an integrated marketing agency that creates and implements clinical trial marketing communications and strategies that are protocol-specific and optimize patient recruitment and retention. SOS and Clinical Solutions share office space in Kennesaw, Georgia, a suburb of Atlanta.
While each company will maintain its individual pharmaceutical and biotech client base, Dr. Demestihas adds, "The merging of SOS and CS operations allows for a broader spectrum of services as well as an increase in management support, additional creative capabilities, and enhanced call center services."
About Science Oriented Solutions (SOS)
SOS, a full-service commercial-side medical affairs group, was established in 1997 as the pharmaceutical industry's first Contract Medical Organization (CMO). SOS focuses on delivering comprehensive outsourcing of medical affairs activities, including Medical Science Liaison (MSL) and medical communications services to pharmaceutical, biotechnology and medical device companies and integrates its activities with the client's core commercial and marketing objectives.
Clinical Solutions, in operation since 1994, is an integrated marketing company exclusively focused on optimizing patient recruitment and retention for clinical trials in a wide range of therapeutic areas. CS is known for developing and implementing protocol-specific programs for pharmaceutical, biotechnology, and medical device companies that are strategic, creative and results oriented.
About Publicis Healthcare Communications Group (PHCG)
Publicis Healthcare Communications Group (PHCG), a member of Publicis Groupe S.A., is the largest healthcare communications group in the world. Worldwide healthcare services include Advertising, Medical Education, Sales and Marketing, Medical and Scientific Affairs, and Healthcare Consulting. PHCG offers its clients a strategic partnership, a strong focus on ensuring value for their marketing spend, and exceptional performance on their assignments.
Publicis Groupe (Euronext Paris: 13057, NYSE: PUB) is the world's fourth largest communications group, and a world leader in media counsel and buying. Services are provided in 109 countries on six continents.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.